Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders

JAMA Oncology

Volumn 2, Issue 2, 2016, Pages 234-240

  Johnson, Douglas B ^a   Sullivan, Ryan J ^b   Ott, Patrick A ^c   Carlino, Matteo S ^d,e   Khushalani, Nikhil I ^f   Ye, Fei ^a   Guminski, Alexander ^e,g   Puzanov, Igor ^a   Lawrence, Donald P ^b   Buchbinder, Elizabeth I ^c   Mudigonda, Tejaswi ^a   Spencer, Kristen ^h   Bender, Carolin ⁱ   Lee, Jenny ^d,g   Kaufman, Howard L ^h   Menzies, Alexander M ^e,g   Hassel, Jessica C ⁱ   Mehnert, Janice M ^h   Sosman, Jeffrey A ^a   Long, Georgina V ^e,g   Clark, Joseph I ^j   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BLACKTOWN HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g MELANOMA INSTITUTE AUSTRALIA   (Australia)

^h RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

ⁱ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^j LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY;

ADULT; AGED; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CLINICAL TRIAL; COMPLICATION; FEMALE; HUMAN; IMMUNOLOGY; MALE; MELANOMA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SKIN NEOPLASMS; TERTIARY CARE CENTER; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85003054266     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.4368     Document Type: Conference Paper

References (32)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): 711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
3. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17): 1889-1894.
4. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.
5. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58(5): 823-830.
6. Weber JS, Dummer R, de Pril V, Lebbé C, Hodi FS; MDX010-20 Investigators. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675-1682.
7. AARDA. The cost burden of autoimmune disease: the latest front in the war on healthcare spending. 2011. American Autoimmune Related Diseases Association website. http://www.diabetesed.net/page/-files/autoimmune-diseases.pdf. Accessed June 15, 2015.
8. Autoimmune Diseases Coordinating Committee. Autoimmune Diseases Research Plan. NIH Pub. No. 03-5140; 2002. http://www.niaid.nih.gov/topics /autoimmune/documents/adccreport.pdf. Accessed June 15, 2015.
9. Kyi C, Carvajal RD,Wolchok JD, PostowMA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2 (1):35.
10. Bostwick AD, Salama AK, Hanks BA. Rapid complete response ofmetastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Cancer. 2015;3:19.
11. Pedersen M, Andersen R, Nørgaard P, et al. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63(12):1341-1346.
12. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
13. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. US Department of Health and Human Services, 2009. http://evs.nci.nih.gov/ftp1 /CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11.pdf. Accessed June 29, 2015.
14. Weber JS, Yang JC, Atkins MB, DisisML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092-2099.
15. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30 (21):2691-2697.
16. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-530.
17. Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-4085.
18. Ryder M, Callahan M, Postow MA,Wolchok J, Fagin JA. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014; 21(2):371-381.
19. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
20. Weber J, Sarnaik A, Targan B. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. J Clin Oncol. 2009;27(15S):9023.
21. O'Day SJ, MaioM, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010;21(8):1712-1717.
22. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-494.
23. Myasoedova E, Davis JMIII, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379-385.
24. Korn EL, Liu PY, Lee SJ, et al.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26(4):527-534.
25. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270(5238): 985-988.
26. Romo-Tena J, Gómez-Martín D, Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev. 2013; 12(12):1171-1176.
27. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
28. Morales RE, Shoushtari AN,Walsh MM, Grewal P, Lipson EJ, Carvajal RD. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer. 2015;3:22.
29. Ranganath HA, Panella TJ. Administration of ipilimumab to a liver transplant recipient with unresectablemetastatic melanoma. J Immunother. 2015;38(5):211.
30. Cecchini M, Sznol M, Seropian S. Immune therapy ofmetastatic melanoma developing after allogeneic bone marrow transplant. J Immunother Cancer. 2015;3:10.
31. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7):1581-1588.
32. Nishimura H, Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502): 319-322.